Patents

Evox Therapeutics, a leading exosome therapeutics company, is pleased to announce that the Company has been granted a key patent by the United States Patent and Trademark Office (USPTO). This newly issued patent adds to the expanding foundational patent estate ...

ILIAS Biologics, a global leader in exosome-based therapeutics, announced today that the Company has been granted a key exosome engineering patent by the United States Patent and Trademark Office (USPTO).A patent for ILIAS's exosome engineering was...

Publication Number WO/2020/133912 Publication Date 02.07.2020 International Application No. PCT/CN2019/089478 International Filing Date 31.05.2019 Provided in the present invention is a method for simultaneously detecting exosome...

The inventions described herein are directed to bispecific antibodies that are capable of selectively targeting exosomes by specifically binding a first exosome-associated protein and Programmed Death Ligand-1 ("PD-L1") as a second exosome-associated protein. These bispecific antibodies can disrupt the suppression of anti-tumor activity by immune cells by...

Aethlon Medical, Inc, a therapeutic medical device and technology company focused on unmet needs in global health, announced today that it has received..

Fluxion Biosciences announced today a foundational patent has been issued for its ERASE-Seq technology, US patent 10,294,518, ‘Methods and Systems for Ultra-sensitive Detection of Genomic Alterations’. The ERASE-Seq technology and testing approach leverage inter-sample statistical analysis, rather than tracking of ...

Evox Therapeutics Ltd, a leading exosome therapeutics company, is pleased to announce that the Company has been granted three key patents by the United States Patent and Trademark Office...

Regeneus, a clinical-stage regenerative medicine company, today announced that the United States Patent Office has issued a notice of allowance for issuance of a patent covering the composition and use of Progenza. Issuance of the patent for United...

Capricor Therapeutics announced today that it has added seven new patent applications to its existing Exclusive License Agreements with Cedars-Sinai Medical Center for technologies related to cardiosphere-derived cells (CDCs) and CDC-derived extracellular vesicles, including exosomes. The Exclusive License Agreements with Cedars-Sinai ...

Capricor Therapeutics today announced that the U.S. Patent and Trademark Office has issued U.S. Patent 9,828,603, which includes composition of matter claims covering cardiosphere-derived cell exosomes. This patent, entitled "Exosomes and Micro...